NCT07564622Not yet recruiting
Gait in Young Children With NF1
Quantitative Gait Metrics to Assess and Predict Gross Motor Impairment in Young Children With Neurofibromatosis Type 1
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
The objective of this study is to develop office-based tools to quantify gait in young children with NF1 that reflect overall gross motor impairment and predict future gross motor difficulties.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 56 (estimated)
- First submitted
- 27 Apr 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Jan 2030
- Lead sponsor
- NYU Langone Health
- NCT number
- NCT07564622
What you commit to
- Study type: Observational
- Planned participants: 56
- From 1 Aug 2026 to the primary completion date, 31 Jan 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age ≥ 6 years old, inability to walk 10 meters independently, non-NF1 medical illness that alters their physical or neurological abilities that could significantly impact their performance.
Other
- Parent/Legal Guardian not willing and able to provide parental consent
Who the study is looking for
- Children who are independently ambulatory who meet revised diagnostic criteria for NF1
- Children less than or equal to 71 months of age
- Parent/Legal Guardian willing and able to provide parental consent.
Age in the registry: - to 71 months · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.